WEST PHARMACEUTICAL SERVICES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 297.48 USD | -1.61% |
|
-0.94% | -15.52% |
Summary: West Pharmaceutical Services, Inc.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Highlights: West Pharmaceutical Services, Inc.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses: West Pharmaceutical Services, Inc.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 45.76 and 37.69 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings Chart: West Pharmaceutical Services, Inc.
Source: Surperformance
ESG chart: West Pharmaceutical Services, Inc.
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 21.58B | |||||
| 203B | |||||
| 115B | |||||
| 68.07B | |||||
| 46.58B | |||||
| 47.28B | |||||
| 29.14B | |||||
| 27.58B | |||||
| 27.19B | |||||
| 24.31B | |||||
| Average | 61.04B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
A-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WST Stock
- Ratings West Pharmaceutical Services, Inc.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition